MSL
MRNA icon

Mackay Shields LLC’s Moderna MRNA Stock Holding History

Mackay Shields LLC’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50,705
Closed -$8.73M – 541
2022
Q1 		$8.73M Sell
50,705
-1,992
-4% -$335K 0.08% 239
2021
Q4 		$13.4M Sell
52,697
-966
-2% -$282K 0.11% 197
2021
Q3 		$20.7M Buy
+53,663
New +$19.8M 0.19% 126
2021
Q2 		– Sell
-37,076
Closed -$4.86M – 1089
2021
Q1 		$4.86M Sell
37,076
-14,526
-28% -$2.1M 0.04% 485
2020
Q4 		$5.39M Sell
51,602
-4,778
-8% -$483K 0.04% 469
2020
Q3 		$3.99M Buy
56,380
+1,491
+3% +$104K 0.03% 501
2020
Q2 		$3.52M Buy
+54,889
New +$3.01M 0.03% 520

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mackay Shields LLC's MRNA Position: Q2 2022 in Review

Mackay Shields LLC sold out of Moderna (MRNA) in Q2 2022, closing a stake of 50,705 shares — an estimated $8.73M sold.

Mackay Shields LLC first reported a position in MRNA in Q2 2020 and held it in 7 quarters. The position peaked at $20.7M in Q3 2021. 981 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

  • Mackay Shields LLC reported no remaining Moderna position as of Q2 2022 after selling out during the quarter.
  • Mackay Shields LLC sold 50,705 Moderna shares in Q2 2022, an estimated $8.73M.
  • Mackay Shields LLC first reported a position in Moderna in Q2 2020 and held it in 7 quarters.
  • Mackay Shields LLC's Moderna position peaked at $20.7M in Q3 2021.
  • 981 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on Mackay Shields LLC's 13F filing for Q2 2022, filed 3 Aug 2022.